Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

A closely tracked personalized melanoma vaccine met its primary goal in a late-stage trial, but its effect on distant spread was far smaller than an earlier study had suggested. The report gives no numerical effect size or trial details.